Piperacillin-Tazobactam versus Cefotaxime as Empiric Treatment for Febrile Urinary Tract Infection in Hospitalized Children
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background According to international pediatric urinary tract infection (UTI) guidelines, selecting ampicillin/sulbactam or amoxicillin/clavulanate is recommended as the first-line treatment for pediatric UTI. In Korea, elevated resistance to ampicillin and ampicillin/sulbactam has resulted in the widespread use of third-generation cephalosporins for treating pediatric UTIs. This study aims to compare the efficacy of piperacillin-tazobactam (TZP) and cefotaxime (CTX) as first-line treatments in hospitalized children with UTIs. Materials and Methods The study, conducted at Jeju National University Hospital, retrospectively analyzed medical records of children hospitalized for febrile UTIs between 2014 and 2017. UTI diagnosis included unexplained fever, abnormal urinalysis, and the presence of significant uropathogens. Treatment responses, recurrence, and antimicrobial susceptibility were assessed. Results Out of 323 patients, 220 met the inclusion criteria. Demographics and clinical characteristics were similar between TZP and CTX groups. For children aged ≥3 months, no significant differences were found in treatment responses and recurrence. Extended-spectrum beta-lactamase (ESBL)-positive strains were associated with recurrence in those <3 months. Conclusion In Korea, escalating resistance to empirical antibiotics has led to the adoption of broad-spectrum empirical treatment. TZP emerged as a viable alternative to CTX for hospitalized children aged ≥3 months with UTIs. Consideration of ESBL-positive strains and individualized approaches for those <3 months are crucial.
Abstract
Background According to international pediatric urinary tract infection (UTI) guidelines, selecting ampicillin/sulbactam or amoxicillin/clavulanate is recommended as the first-line treatment for pediatric UTI. In Korea, elevated resistance to ampicillin and ampicillin/sulbactam has resulted in the widespread use of third-generation cephalosporins for treating pediatric UTIs. This study aims to compare the efficacy of piperacillin-tazobactam (TZP) and cefotaxime (CTX) as first-line treatments in hospitalized children with UTIs. Materials and Methods The study, conducted at Jeju National University Hospital, retrospectively analyzed medical records of children hospitalized for febrile UTIs between 2014 and 2017. UTI diagnosis included unexplained fever, abnormal urinalysis, and the presence of significant uropathogens. Treatment responses, recurrence, and antimicrobial susceptibility were assessed. Results Out of 323 patients, 220 met the inclusion criteria. Demographics and clinical characteristics were similar between TZP and CTX groups. For children aged ≥3 months, no significant differences were found in treatment responses and recurrence. Extended-spectrum beta-lactamase (ESBL)-positive strains were associated with recurrence in those <3 months. Conclusion In Korea, escalating resistance to empirical antibiotics has led to the adoption of broad-spectrum empirical treatment. TZP emerged as a viable alternative to CTX for hospitalized children aged ≥3 months with UTIs. Consideration of ESBL-positive strains and individualized approaches for those <3 months are crucial.
참고문헌 (32)
- Roberts KB, "Revised AAP guideline on UTI in febrile infants and young children", Am Fam Physician, 86, pp.940~946 (2012)
- Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, "Urinary tract infection : clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months", Pediatrics, 128, pp.595~610 (2011)
- ". Urinary tract infection under 16s: diagnosis and management" (2022)[URL]
- Ammenti A, "Updated Italian recommendations for the diagnosis, treatment and follow-up of the first febrile urinary tract infection in young children", Acta Paediatr, 109, pp.236~247 (2020)
- Robinson JL, "Urinary tract infections in infants and children : Diagnosis and management", Paediatr Child Health, 19, pp.315~325 (2014)
- Vazouras K, "Antibiotic treatment and antimicrobial resistance in children with urinary tract infections", J Glob Antimicrob Resist, 20, pp.4~10 (2020)
- Kang CI, "Clinical practice guidelines for the antibiotic treatment of community-acquired urinary tract infections", Infect Chemother, 50, pp.67~100 (2018)
- Kim E, "Clinical outcomes of non-carbapenem treatment for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli", Child Kidney Dis, 25, pp.22~28 (2021)
- "Guidelines for childhood urinary tract infection"[URL]
- Choi U, "The change of antibiotic susceptibility in febrile urinary tract infection in childhood and adolescence during the last decade", Investig Clin Urol, 63, pp.99~106 (2022)
- Dancer SJ, "The problem with cephalosporins", J Antimicrob Chemother, 48, pp.463~478 (2001)
- Lee YK, "The antibiotic resistance pattern of Gram-negative bacteria in children younger than 24 months with a urinary tract infection : a retrospective single-center study over 15 consecutive years", Child Kidney Dis, 19, pp.148~153 (2015)
- Flokas ME, "Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections : a systematic review and meta-analysis", J Infect, 73, pp.547~557 (2016)
- Guervil DJ, "Trends in multidrug-resistant Gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit", Crit Care Nurs Q, 36, pp.345~355 (2013)
- Paterson DL, "The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals", Clin Infect Dis, 42(Suppl 2), pp.S90~S95 (2006)
- Lee J, "Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy", J Antimicrob Chemother, 60, pp.629~637 (2007)
- Bader MS, "An update on the management of urinary tract infections in the era of antimicrobial resistance", Postgrad Med, 129, pp.242~258 (2017)
- Lee H, "Predictive markers for screening renal damage in children with urinary tract infections and vesicoureteral reflux", Child Kidney Dis, 24, pp.27~35 (2020)
- Herzog L, "Addressing concerns about fever", Clin Pediatr(Phila), 50, pp.383~390 (2011)
- Pohl HG, "The"top-down"approach to the evaluation of children with febrile urinary tract infection", Adv Urol, 2009, pp.783409~ (2009)
- Bae EY, "Clinical characteristics and antibiotic resistance of urinary tract infections in children : Escherichia. coli versus non-E. coli", Korean J Pediatr Infect Dis, 17, pp.67~73 (2010)
- Autore G, "Management of pediatric urinary tract infections : a delphi study", Antibiotics(Basel), 11, pp.1122~ (2022)
- Stamey TA, "Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections", N Engl J Med, 291, pp.1159~1163 (1974)
- Tzialla C, "Neonatal infections due to multi-resistant strains : epidemiology, current treatment, emerging therapeutic approaches and prevention", Clin Chim Acta, 451, pp.71~77 (2015)
- Hyun HS, "Low relapse rate of urinary tract infections from extended-spectrum beta-lactamase-producing bacteria in young children", Pediatr Nephrol, 34, pp.2399~2407 (2019)
- Sharara SL, "Is Piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum β-lactamase-producing organisms?", Clin Infect Dis, 71, pp.e331~e337 (2020)
- Islam K, "Pharmacodynamics of piperacillin-tazobactam", amikacin combination versus meropenem against extended-spectrum β-lactamase-producing Escherichia coli in a hollow fiber infection model, 2022, pp.66, e0016222~
- Kim YH, "Urinary tract infection caused by community-acquired extended-spectrum β-lactamase-producing bacteria in infants", J Pediatr(Rio J), 93, pp.260~266 (2017)
- Seo EY, "Clinical study of prevalence of antibiotic resistance of Escherichia coli in urinary tract infection in children : a 9-year retrospective, single center experience", Child Kidney Dis, 21, pp.121~127 (2017)
- Kim YA, "Trends in South Korean antimicrobial use and association with changes in Escherichia coli resistance rates : 12-year ecological study using a nationwide surveillance and antimicrobial prescription database", PLoS One, 13, pp.e0209580~ (2018)
- Han SB, "Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae", BMC Infect Dis, 15, pp.414~ (2015)
- Goodlet KJ, "A systematic review of single-dose aminoglycoside therapy for urinary tract infection : is it time to resurrect an old strategy?", Antimicrob Agents Chemother, 63, pp.e02165-18~ (2018)